Market Overview:
The global uterine fibroids market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as the increasing prevalence of uterine fibroids, rising awareness about available treatment options, and technological advancements in the field of uterine fibroid treatment. Based on type, the global uterine fibroids market is segmented into non-hormonal treatment and hormonal treatment. Non-hormonal treatments are further sub-segmented into surgery and other treatments. Hormonal treatments are sub-segmented into oral contraceptives and hormone therapy injections. Oral contraceptives are further sub-segmented into combined oral contraceptives (COCs) and progestin only pills (POPs). Hormone therapy injections are further sub-segmented into gonadotropin releasing hormone agonists (GnRH agonists) and selective estrogen receptor modulators (SERMs). Based on application, the global uterine fibroid market is segmented into hospitals, ambulatory surgical centers, diagnostic centers, and others. Geographically, the global uterus Fibroid Market is segmentedinto North America , Latin America , Europe Asia Pacific , Middle East & Africa .
Product Definition:
A uterine fibroid is a benign tumor that forms in the muscle tissue of the uterus. Uterine fibroids are very common and can occur in women of any age.
Non-Hormonal Treatment:
Non-hormonal treatment is a category of medical treatments that do not include hormonal therapies such as oral contraceptives, estrogen, or testosterone. Non-hormonal treatments are used to reduce the size of uterine fibroids and/or prevent their growth.
Uterine Fibroid Treatment Market By Region (North America [The U.S.
Hormonal Treatment:
Hormonal treatment is a medical intervention used to imbalance the hormonal activity in the body, which helps shrink or eliminate fibroids (unwanted fat) in the uterus. Hormonal treatments include oral contraceptives, birth control pills, estrogen therapy and other related drugs.
Uterine Fibroids Market Size & Forecasts by Type (Follicular Hyperplasia, Endometriosis), by Treatment.
Application Insights:
Based on application, the global uterine fibroids market is segmented into hospitals, ambulatory surgical centers, diagnostic centers and others. The hospitals segment dominated the overall market in terms of revenue in 2017 owing to increasing awareness about hysterectomy procedures among women as a result of which they prefer to undergo treatment at hospital settings. In addition, rising prevalence of chronic conditions such as diabetes and high cost associated with medical treatment are factors contributing towards growth in demand for hysterectomy procedures at a global level.
The Ambulatory Surgical Centers (ASCs) segment is expected to grow significantly over the forecast period due to growing awareness about available treatments coupled with increasing availability of advanced equipment for diagnosing uterine fibroids at ASCs. Furthermore, an increase in number of ASCs due to rise in incidence rates has further increased accessibility for patients suffering from heavy bleeding or pain during sex without any prior notice throughout their life span thus driving demand globally over recent years.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing government initiatives are some factors responsible for its growth. For instance, in 2014, the Patient Protection and Affordable Care Act (PPACA) mandated that all health insurance providers cover part or all of the cost of fibroids removal procedures. This is expected to increase access to these procedures over time.
In addition, a growing number of international trade activities with developed economies coupled with increased focus on exports by various developing nations will drive this regional market further.
Growth Factors:
- Increasing incidence of uterine fibroids
- Growing awareness about the available treatment options for uterine fibroids
- Rising prevalence of obesity and other lifestyle-related risk factors for uterine fibroids
- Advances in diagnostic technologies and treatments for uterine fibroids
- Increased focus on women's health issues
Scope Of The Report
Report Attributes
Report Details
Report Title
Uterine Fibroids Market Research Report
By Type
Non-Hormonal Treatment, Hormonal Treatment
By Application
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Others
By Companies
Boston Scientific, Cooper Surgical, C.R. Bard, F. Hoffmann-La Roche, GE Healthcare, Karl Storz Endoscopy, Richard Wolf Medical Instruments, Siemens Medical Solutions, AbbVie, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline Pharmaceuticals, Pfizer, Johnson & Johnson, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
217
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Uterine Fibroids Market Report Segments:
The global Uterine Fibroids market is segmented on the basis of:
Types
Non-Hormonal Treatment, Hormonal Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boston Scientific
- Cooper Surgical
- C.R. Bard
- F. Hoffmann-La Roche
- GE Healthcare
- Karl Storz Endoscopy
- Richard Wolf Medical Instruments
- Siemens Medical Solutions
- AbbVie
- AstraZeneca
- Bayer
- Eli Lilly
- GlaxoSmithKline Pharmaceuticals
- Pfizer
- Johnson & Johnson
- Novartis
Highlights of The Uterine Fibroids Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Non-Hormonal Treatment
- Hormonal Treatment
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Uterine Fibroids Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Uterine fibroids are benign tumors that grow in the uterus. They can cause pain, heavy periods, and difficulty getting pregnant. Uterine fibroids may also lead to other health problems if they are large or close to the womb (uterus).
Some of the major companies in the uterine fibroids market are Boston Scientific, Cooper Surgical, C.R. Bard, F. Hoffmann-La Roche, GE Healthcare, Karl Storz Endoscopy, Richard Wolf Medical Instruments, Siemens Medical Solutions, AbbVie, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline Pharmaceuticals, Pfizer, Johnson & Johnson, Novartis.
The uterine fibroids market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Uterine Fibroids Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Uterine Fibroids Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Uterine Fibroids Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Uterine Fibroids Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Uterine Fibroids Market Size & Forecast, 2020-2028 4.5.1 Uterine Fibroids Market Size and Y-o-Y Growth 4.5.2 Uterine Fibroids Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Non-Hormonal Treatment
5.2.2 Hormonal Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Diagnostic Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Uterine Fibroids Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Uterine Fibroids Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Non-Hormonal Treatment
9.6.2 Hormonal Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Diagnostic Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Non-Hormonal Treatment
10.6.2 Hormonal Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Diagnostic Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Non-Hormonal Treatment
11.6.2 Hormonal Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Diagnostic Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Non-Hormonal Treatment
12.6.2 Hormonal Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Diagnostic Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Non-Hormonal Treatment
13.6.2 Hormonal Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Diagnostic Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Uterine Fibroids Market: Competitive Dashboard
14.2 Global Uterine Fibroids Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boston Scientific
14.3.2 Cooper Surgical
14.3.3 C.R. Bard
14.3.4 F. Hoffmann-La Roche
14.3.5 GE Healthcare
14.3.6 Karl Storz Endoscopy
14.3.7 Richard Wolf Medical Instruments
14.3.8 Siemens Medical Solutions
14.3.9 AbbVie
14.3.10 AstraZeneca
14.3.11 Bayer
14.3.12 Eli Lilly
14.3.13 GlaxoSmithKline Pharmaceuticals
14.3.14 Pfizer
14.3.15 Johnson & Johnson
14.3.16 Novartis